2019 American Society of Hematology Annual Meeting*

Download All
December 7-10, 2019; Orlando, Florida
Review slidesets and analyses of key data from the 2019 Hematology meeting.

Lymphomas and Chronic Lymphocytic Leukemia

Capsule Summary Slidesets

In the pivotal phase I TRANSCEND NHL 001 study, the CD19-directed CAR T-cell therapy lisocabtagene maraleucel demonstrated robust activity and manageable safety in relapsed/refractory LBCL.

Released: December 12, 2019

Acalabrutinib with or without obinutuzumab significantly improved PFS compared with obinutuzumab plus chlorambucil.

Released: December 11, 2019

Combination therapy with acalabrutinib, venetoclax, and obinutuzumab is highly active and safe as frontline therapy in CLL.

Released: December 9, 2019

Venetoclax plus ibrutinib combination regimen in high-risk untreated patients with CLL showed increasing MRD negativity with continued treatment up to 2 years.

Released: December 13, 2019

Initial results from the phase II CAPTIVATE trial demonstrated that ibrutinib plus venetoclax yielded high rates of undetectable MRD in patients with previously untreated CLL/SLL.

Released: December 11, 2019

LOXO-305, a non-covalent BTK inhibitor, demonstrated preliminary antitumor activity and manageable safety in pretreated B-cell malignancies including those resistant to previous BTKi therapy.

Released: December 19, 2019

Lisocabtagene maraleucel showed manageable toxicity and clinical activity in heavily pretreated patients with high-risk CLL/SLL who failed prior ibrutinib.

Released: December 19, 2019

CRs observed with single-agent mosunetuzumab, a bispecific antibody, in patients with R/R B-cell NHL, including patients with aggressive disease.

Released: December 12, 2019

Patients with relapsed/refractory B-cell NHL who showed clinical response to liso-cel reported greater quality-of-life improvement vs nonresponders.

Released: December 17, 2019

KTE-X19, a CD19-directed CAR T-cell therapy, produced high and durable response rates in relapsed/refractory mantle cell lymphoma.

Released: December 15, 2019

Despite axi-cel being used in older patients and in more patients with high-risk disease, real-world efficacy and safety data for axi-cel in patients with large B-cell lymphoma was comparable to findings from the registrational ZUMA-1 trial.

Released: December 16, 2019
Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Celgene Corporation
Dova Pharmaceuticals, Inc.
Karyopharm Therapeutics
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings